Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Opinion CV Team Dispatch

June 2025 Dispatch for the CV Team

L.A. McKeown

June 26, 2025

News Daily News

Childhood Risk Factors Predict Later CVD Risk

L.A. McKeown

June 28, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

News Daily News

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Todd Neale

November 22, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Michael O'Riordan

February 06, 2020

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

Shelley Wood

April 02, 2018

News Features

Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits

Michael O'Riordan

November 11, 2016

News Conference News ESC 2016

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Todd Neale

August 29, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

Advertisement

June 2025 Dispatch for the CV Team

Childhood Risk Factors Predict Later CVD Risk

March 2024 Dispatch for the CV Team

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Top News in Policy & Practice: 2018

TCTMD’s Top 10 Most Popular Stories for March 2018

Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content